Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

508
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
508
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

533
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
533
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

825
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
825
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Absence of coronary artery disease in patients undergoing coronary imaging and association with amyloidosis: A Danish nationwide study.

American heart journal·2025
Same author

First-in-Human Experience With a Biventricular, Pulsatile MCS Platform Technology Avoiding Blood Contact: Translational Insights.

JACC. Basic to translational science·2025
Same author

Influence of Obesity on Invasive Hemodynamics and Prognosis in Patients With Heart Failure.

JACC. Heart failure·2025
Same author

Ventricular arrhythmias in acute heart failure. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Heart Rhythm Association (EHRA) and the Heart Failure Association (HFA) of the ESC.

European journal of heart failure·2025
Same author

Understanding Platelet Activation in the Aeson Bioprosthetic Total Artificial Heart: Insights From Aspirin Treatment and Outcomes.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2025
Same author

Adenovirus Infections and Disease in Solid Organ Transplant Recipients: Incidence and Outcomes.

Open forum infectious diseases·2025
Same journal

Cardiovascular disease and miRNA.

Advances in clinical chemistry·2026
Same journal

RNA biomarkers in antidoping.

Advances in clinical chemistry·2026
Same journal

Biomarkers for assessing magnesium status.

Advances in clinical chemistry·2026
Same journal

Advances in microfluidic extracellular vesicle technology.

Advances in clinical chemistry·2026
Same journal

Chronic low-grade inflammation in vegetarians and vegans: Biomarker evidence and methodological considerations.

Advances in clinical chemistry·2026
Same journal

Biomarkers in heart failure.

Advances in clinical chemistry·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Copeptin in Heart Failure.

Louise Balling1, Finn Gustafsson1

  • 1Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Advances in Clinical Chemistry
|March 16, 2016
PubMed
Summary
This summary is machine-generated.

Heart failure (HF) requires better monitoring tools. Copeptin, a novel biomarker, shows promise in tracking disease severity and predicting patient outcomes in heart failure.

Keywords:
AVPBiomarkerCopeptinHeart failureHyponatremiaNeurohormonal activationOsmoregulationVasopressin

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.1K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.5K

Related Experiment Videos

Last Updated: Mar 24, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.1K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.5K

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Medicine

Background:

  • Heart failure (HF) is a leading cause of hospitalization and mortality, with high mortality rates despite current treatments.
  • Existing medical management focuses on neurohormonal blockade, but effective single markers for HF progression, hospitalization, or mortality are lacking.
  • There is a critical need for new diagnostic and prognostic tools in HF management.

Purpose of the Study:

  • To investigate the potential of copeptin as a novel biomarker in heart failure (HF).
  • To assess copeptin's association with HF severity, prognosis, and survival.
  • To explore the utility of copeptin, potentially in combination with other biomarkers, for monitoring HF.

Main Methods:

  • The study focused on analyzing copeptin levels in patients with acute and chronic heart failure.
  • Investigated the correlation between copeptin levels and established HF metrics.
  • Evaluated copeptin's predictive value for prognosis and survival.

Main Results:

  • Copeptin levels were found to be elevated in both acute and chronic heart failure patients.
  • Elevated copeptin levels were associated with a poorer prognosis in HF.
  • The study suggests copeptin's potential as a prognostic indicator.

Conclusions:

  • Copeptin is a promising new biomarker for heart failure (HF).
  • Elevated copeptin levels indicate a worse prognosis and are linked to mortality in HF.
  • Copeptin, possibly combined with other biomarkers, could enhance HF monitoring and prediction.